7 miRNA: combined sample

Author: Lucas Toshio Ito
lucas.toshio.ito@gmail.com
Universidade Federal de São Paulo (UNIFESP)

Last updated: March 16, 2026

Counts represent raw availability before modality-specific quality control. Cumulative cases are participants who met the phenotype definition at any observed timepoint; missing assessments are skipped.

Psychiatric Disorders (DAWBA):

Attention-Deficit/Hyperactivity Disorder (ADHD): dcanyhk
Anxiety Disorder: dcpanic; dcagor; dcgena; dcsoph; dcspph
Bipolar Disorder / Mania: dcmania
Eating Disorder: dceat
Major Depressive Disorder (MDD): dcmadep
Obsessive–Compulsive Disorder (OCD): dcocd
Psychosis: dcpsych
Post-Traumatic Stress Disorder (PTSD): dcptsd
Any Psychiatric Disorder: dcany

Suicidality variables (C-SSRS):

Suicidal Ideation (SI): p_colbi1_lt, p_colbi2_lt
Suicide Attempt (SA): p_colbsb1a_lt, p_colbsb2a_lt, p_colbsb3a_lt

7.1 Demographic Characteristics

Demographic Characteristics of the Study Sample
Variable	Wave0 N = 58¹	Wave1 N = 198¹	Wave2 N = 198¹	Wave3 N = 132¹	Overall N = 198²
Sex at birth
Male	34 (58.6%)	119 (60.1%)	119 (60.1%)	83 (62.9%)	119 (60.1%)
Female	24 (41.4%)	79 (39.9%)	79 (39.9%)	49 (37.1%)	79 (39.9%)
Age
Mean (SD)	10.3 (1.5)	14.4 (1.8)	17.9 (1.9)	23.4 (1.8)	23.2 (2.1)
Median (Q1-Q3)	10.3 (9.2-11.3)	14.3 (13.0-15.7)	17.8 (16.3-19.4)	23.4 (21.9-24.7)	23.2 (21.7-24.6)
State
RS	0 (0.0%)	69 (34.8%)	69 (34.8%)	34 (25.8%)	69 (34.8%)
SP	58 (100.0%)	129 (65.2%)	129 (65.2%)	98 (74.2%)	129 (65.2%)
Selection
Random	32 (55.2%)	87 (43.9%)	87 (43.9%)	58 (43.9%)	87 (43.9%)
High Risk	26 (44.8%)	111 (56.1%)	111 (56.1%)	74 (56.1%)	111 (56.1%)
Skin color
White	24 (41.4%)	105 (53.0%)	105 (53.0%)	68 (51.5%)	105 (53.0%)
Black	5 (8.6%)	22 (11.1%)	22 (11.1%)	15 (11.4%)	22 (11.1%)
Between white and black (brown)	29 (50.0%)	70 (35.4%)	70 (35.4%)	48 (36.4%)	70 (35.4%)
Indigenous	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Asian	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.8%)	1 (0.5%)
¹ n (%)
² Overall N includes participants with miRNA data at any timepoint and reflects data from their most recent assessment.

7.2 Wave-Specific Psychiatric Phenotypes

Wave-Specific Psychiatric Phenotypes Prevalence Among Probands with miRNA Data (BHRC)
Psychiatric Phenotype	Wave 0 (N=58)	Wave 1 (N=198)	Wave 2 (N=198)	Wave 3 (N=132)	Lifetime (N=198)¹
ADHD	7 (12.1%)	20 (10.1%)	13 (6.6%)	5 (3.8%)	57 (28.8%)
Anxiety Disorders	2 (3.4%)	29 (14.6%)	33 (16.7%)	25 (18.9%)	76 (38.4%)
Bipolar Disorder or Mania	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (2.3%)	5 (2.5%)
Eating Disorders	0 (0.0%)	1 (0.5%)	2 (1.0%)	1 (0.8%)	5 (2.5%)
Major Depressive Disorder	0 (0.0%)	26 (13.1%)	43 (21.7%)	15 (11.4%)	69 (34.8%)
OCD	0 (0.0%)	4 (2.0%)	2 (1.0%)	2 (1.5%)	9 (4.5%)
Psychosis	0 (0.0%)	1 (0.5%)	2 (1.0%)	0 (0.0%)	3 (1.5%)
PTSD	1 (1.7%)	4 (2.0%)	4 (2.0%)	5 (3.8%)	19 (9.6%)
Any Psychiatric Disorder	13 (22.4%)	83 (41.9%)	73 (36.9%)	47 (35.6%)	140 (70.7%)
Suicidal Ideation²	0 (0.0%)	0 (0.0%)	0 (0.0%)	50 (37.9%)	81 (40.9%)
Suicide Attempt²	0 (0.0%)	0 (0.0%)	0 (0.0%)	27 (20.5%)	49 (24.7%)
¹ Lifetime N represents the phenotype at any assessment among participants with miRNA data.
² Suicidality phenotypes were only evaluated in the last follow-up (Wave 3).
Diagnoses were assessed using the Development and Well-Being Assessment (DAWBA) following DSM-IV criteria. The table summarizes psychiatric disorders identified among probands at each assessment wave.

7.3 Cumulative Psychiatric Phenotypes

Cumulative Psychiatric Phenotypes Prevalence Across Waves Among Probands with miRNA Data (BHRC)
Psychiatric Phenotype	Wave 0 (N=58)	Wave 1 (N=198)	Wave 2 (N=198)	Wave 3 (N=132)	Lifetime (N=198)¹
ADHD	7 (12.1%)	46 (23.2%)	52 (26.3%)	34 (25.8%)	57 (28.8%)
Anxiety Disorders	2 (3.4%)	41 (20.7%)	64 (32.3%)	47 (35.6%)	76 (38.4%)
Bipolar Disorder or Mania	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (2.3%)	5 (2.5%)
Eating Disorders	0 (0.0%)	2 (1.0%)	4 (2.0%)	3 (2.3%)	5 (2.5%)
Major Depressive Disorder	0 (0.0%)	30 (15.2%)	60 (30.3%)	35 (26.5%)	69 (34.8%)
OCD	0 (0.0%)	5 (2.5%)	7 (3.5%)	4 (3.0%)	9 (4.5%)
Psychosis	0 (0.0%)	1 (0.5%)	3 (1.5%)	1 (0.8%)	3 (1.5%)
PTSD	1 (1.7%)	7 (3.5%)	11 (5.6%)	11 (8.3%)	19 (9.6%)
Any Psychiatric Disorder	13 (22.4%)	109 (55.1%)	128 (64.6%)	83 (62.9%)	140 (70.7%)
Suicidal Ideation²	0 (0.0%)	0 (0.0%)	0 (0.0%)	50 (37.9%)	81 (40.9%)
Suicide Attempt²	0 (0.0%)	0 (0.0%)	0 (0.0%)	27 (20.5%)	49 (24.7%)
¹ Lifetime N represents the phenotype at any assessment among participants with miRNA data.
² Suicidality phenotypes were only evaluated in the last follow-up (Wave 3).
Diagnoses were assessed using the Development and Well-Being Assessment (DAWBA) following DSM-IV criteria. The table summarizes lifetime psychiatric disorders identified in probands up to each wave. Phenotypes are counted from the wave of first identification onward.

7.4 Diagnosis Timing Relative to miRNA Acquisition

A diagnosis is counted by acquisition when identified in the same or an earlier wave. Age-18+ diagnoses use p1dawbaage or sdawbaage.

Exclusions

Pre-18-only cases and diagnoses first observed after acquisition are excluded from controls. Participants without an age-18+ evaluation fall outside the adult denominator.

Psychiatric Diagnosis Timing Among Probands with miRNA Data (BHRC)
Cell format: cases / controls / excluded lifetime cases
Psychiatric Phenotype	Lifetime (N=198)	Diagnosed at 18+ (N=195)	By miRNA wave (N=198)	At 18+ by miRNA wave (N=167)
ADHD	57 / 141 / 0	15 / 139 / 41	54 / 141 / 3	12 / 124 / 31
Anxiety Disorders	76 / 122 / 0	45 / 120 / 30	74 / 122 / 2	37 / 103 / 27
Bipolar Disorder or Mania	5 / 193 / 0	4 / 190 / 1	4 / 193 / 1	3 / 163 / 1
Eating Disorders	5 / 193 / 0	3 / 190 / 2	5 / 193 / 0	3 / 163 / 1
Major Depressive Disorder	69 / 129 / 0	43 / 127 / 25	68 / 129 / 1	38 / 111 / 18
OCD	9 / 189 / 0	4 / 186 / 5	8 / 189 / 1	2 / 160 / 5
Psychosis	3 / 195 / 0	2 / 192 / 1	3 / 195 / 0	2 / 164 / 1
PTSD	19 / 179 / 0	9 / 176 / 10	16 / 179 / 3	6 / 151 / 10
Any Psychiatric Disorder	140 / 58 / 0	88 / 57 / 50	139 / 58 / 1	76 / 51 / 40
Cells show cases / controls / excluded cases. Controls were assessed and never positive. Pre-18-only cases are excluded from adult controls; 3 participants lacked an age-18+ evaluation. Diagnoses first observed after the relevant miRNA wave are excluded from acquisition-aligned controls.